Posted by Michael Wonder on 12 Feb 2026
ICER publishes final evidence report on medication for smoking cessation
12 February 2026 - Independent appraisal committee votes reflect a net health benefit for cytisinicline alone, but uncertainty when compared to varenicline; manufacturer setting a price for cytisinicline to align with value would help ensure public health goals for smoking cessation are met.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of cytisinicline (Achieve Life Sciences) for smoking cessation. Our primary comparison was with the smoking cessation drug, varenicline.
